Please use this identifier to cite or link to this item:
Title: Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients.
Issue Date: 5-Nov-2020
Citation: J Neurol Neurosurg Psychiatry.2020;():
Abstract: To study baseline serum neurofilament light chain (sNfL) levels as a prognostic biomarker in Guillain-Barré syndrome (GBS). We measured NfL in serum (98 samples) and cerebrospinal fluid (CSF) (24 samples) of patients with GBS prospectively included in the International GBS Outcome Study (IGOS) in Spain using single-molecule array (SiMoA) and compared them with 53 healthy controls (HCs). We performed multivariable regression to analyse the association between sNfL levels and functional outcome at 1 year. Patients with GBS had higher NfL levels than HC in serum (55.49 pg/mL vs 9.83 pg/mL, p319 pg/mL), inability to run (>248 pg/mL) and ability to run (248 pg/mL) and ability to run ( Baseline sNfL levels are increased in patients with GBS, are associated with disease severity and axonal variants and have an independent prognostic value in patients with GBS.
PMID: 33154183
Appears in Collections:Fundaciones e Institutos de Investigación > FIIB H. U. Infanta Sofía y H. U. Henares > Artículos

Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.

This item is licensed under a Creative Commons License Creative Commons